EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial

Sophie Gottschalk iD, Shinwan Kany iD, Hans-Helmut König iD, Harry Jgm Crijns iD, Panos Vardas iD, A John Camm, Karl Wegscheider iD, Andreas Metzner iD, Andreas Rillig iD, Paulus Kirchhof iD, Judith Dams iD

Europace · 2023

DOI: 10.1093/europace/euad051 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2023. Verfasst von Sophie Gottschalk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martin…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Failure, Stroke. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Heart Foundation, German Ministry of Education and Research, German Centre for Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The randomized, controlled EAST-AFNET 4 trial showed that early rhythm control (ERC) reduces the rate of a composite primary outcome (cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome) by ∼20%. The current study examined the cost-effectiveness of ERC compared to usual care. Methods and results This within-trial cost-effectiveness analysis was based on data from the German subsample of the EAST-AFNET 4 trial (n = 1664/2789 patients). Over a 6-year time horizon and from a healthcare payer’s perspective, ERC was compared to usual care regarding costs (hospitalization and medication) and effects (time to primary outcome; years survived). Incremental cost-effectiveness ratios (ICERs) were calculated. Cost-effectiveness acceptability curves were constructed to visualize uncertainty. Early rhythm control was associated with higher costs [+€1924, 95% CI (−€399, €4246)], resulting in ICERs of €10 638 per additional year without a primary outcome and €22 536 per life year gained. The probability of ERC being cost-effective compared to usual care was ≥95% or ≥80% at a willingness-to-pay value of ≥€55 000 per additional year without a primary outcome or life year gained, respectively.

Conclusion

From a German healthcare payer’s perspective, health benefits of ERC may come at reasonable costs as indicated by the ICER point estimates. Taking statistical uncertainty into account, cost-effectiveness of ERC is highly probable at a willingness-to-pay value of ≥€55 000 per additional life year or year without a primary outcome. Future studies examining the cost-effectiveness of ERC in other countries, subgroups with higher benefit from rhythm control therapy, or cost-effectiveness of different modes of ERC are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart FailureStrokeHumansCost-Benefit AnalysisCost-Effectiveness AnalysisQuality-Adjusted Life Years

Stichwörter der Autor:innen

Atrial fibrillationCost-effectivenessEarly rhythm control

Autor:innen und Institutionen

  • Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martinistraße 52 Building W37, 20246 Hamburg, Germany.
  • Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany.
  • German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany.
  • Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Universiteitssingel 50, 6200 MD, Maastricht, The Netherlands.
  • European Society of Cardiology Health Policy Unit, European Heart Health Institute, European Heart Agency, 29 square de Meeus, B-1000 Brussels, BELGIUM.
  • Molecular & Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, London SW17 0RE, UK.

ORCID-Profile: Sophie Gottschalk, Shinwan Kany, Hans-Helmut König, Harry Jgm Crijns, Panos Vardas, Karl Wegscheider, Andreas Metzner, Andreas Rillig, Paulus Kirchhof, Judith Dams

Förderung

  • British Heart Foundation
  • German Ministry of Education and Research
  • German Centre for Cardiovascular Research
  • Atrial Fibrillation Network
  • European Heart Rhythm Association
  • Sanofi
  • German Heart Foundation

Zitieren

APA

Gottschalk, S., Kany, S., König, H. H., Crijns, H. J., Vardas, P., Camm, A. J., Wegscheider, K., Metzner, A., Rillig, A., Kirchhof, P., & Dams, J. (2023). Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial. Europace. https://doi.org/10.1093/europace/euad051

Vancouver

Gottschalk S, Kany S, König HH, Crijns HJ, Vardas P, Camm AJ, et al. Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial. Europace. 2023. doi:10.1093/europace/euad051

BibTeX
@article{Gottschalk2023,
  author = {Gottschalk, Sophie and Kany, Shinwan and König, Hans-Helmut and Crijns, Harry Jgm and Vardas, Panos and Camm, A John and Wegscheider, Karl and Metzner, Andreas and Rillig, Andreas and Kirchhof, Paulus and Dams, Judith},
  title = {Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad051}
}
Kostenlos starten →